BioEclipse Therapeutics has developed a new generation of precise, targeted, immunotherapies that bring hope to patients with advanced cancer who have few treatment options.
The first therapeutic from our platform, currently in Phase 1b/2a, was developed for increased potency that provides three non-overlapping mechanisms of action to conquer the challenges of resistant and recurrent cancers and for the ability to scale our manufacturing process.